On June 15, 2021 Enlivex Therapeutics Ltd., (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, reported that the European Patent Office has issued European patent No. 3,258,943 covering AllocetraTM, the Company’s immunotherapy product candidate. The new patent’s title is "COMBINATION IMMUNE THERAPY AND CYTOKINE CONTROL THERAPY FOR CANCER TREATMENT", and is expected to provide added intellectual property protection for therapeutic compositions of AllocetraTM and CAR-T immunotherapies for inhibition or reduction of cytokine storms associated with CAR-T therapies for cancer (Press release, Enlivex Therapeutics, JUN 15, 2021, View Source [SID1234584019]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Oren Hershkovitz, PhD, CEO of Enlivex, stated, "We are pleased to have this patent granted in Europe, which adds to existing AllocetraTM patents in various countries around the world. Specifically, this new patent further strengthens our existing intellectual property portfolio covering the use of AllocetraTM for cancer therapy."
AllocetraTM is being developed as a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as "unmet medical needs", as a stand-alone therapy or in combination with leading therapeutic agents.